All Articles

On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years with relapsed or refractory CD33-positive AML.

On behalf of all of us at the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Journal of Oncology Navigation & Survivorship (JONS), it is my pleasure and honor to wish you a joyful holiday season and continued blessings in 2018.

Nurse Navigator Amy Jo Pixley reveals how she organizes her day, prioritizes her work load, implements metrics, and cares for individual patients.

The authors examine and assess the effect of a nurse navigator home visit in reducing distress among women who have been newly diagnosed with breast cancer.

A psychological intervention called Managing Cancer and Living Meaningfully (CALM), specifically developed for people with advanced/metastatic cancer, reduced depressive symptoms and the chances of developing depression compared with usual care, according to results of a randomized trial presented at the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer

At the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer, Dr. Jeanne Carter shared research from her program at MSKDD to update attendees on current finding, newer assessment instruments, and clinical tools to identify sexual health concern in women with cancer.

In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.

In an effort to understand a day in the life of a thoracic navigator, we spent some time with Wendy Brooks, RN, ONN-CG. Ms Brooks obtained her certification as generalist oncology nurse navigator through the Academy of Oncology Nurse & Patient Navigators (AONN+) and was instrumental in the development of the AONN+ specialty certification exam in thoracic oncology.

To be effective, navigators are required to stay up to date on the constantly changing landscape of lung cancer care.